190 related articles for article (PubMed ID: 9267828)
41. Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status.
Hong H; Kao C; Jeng MH; Eble JN; Koch MO; Gardner TA; Zhang S; Li L; Pan CX; Hu Z; MacLennan GT; Cheng L
Cancer; 2004 Jul; 101(1):83-9. PubMed ID: 15221992
[TBL] [Abstract][Full Text] [Related]
42. Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line.
Wang LG; Ossowski L; Ferrari AC
Cancer Res; 2001 Oct; 61(20):7544-51. PubMed ID: 11606392
[TBL] [Abstract][Full Text] [Related]
43. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.
Rubin MA; Mucci NR; Figurski J; Fecko A; Pienta KJ; Day ML
Hum Pathol; 2001 Jul; 32(7):690-7. PubMed ID: 11486167
[TBL] [Abstract][Full Text] [Related]
44. Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy.
Rosner IL; Ravindranath L; Furusato B; Chen Y; Gao C; Cullen J; Sesterhenn IA; McLeod DG; Srivastava S; Petrovics G
Urology; 2007 Dec; 70(6):1225-9. PubMed ID: 18158066
[TBL] [Abstract][Full Text] [Related]
45. BRCA1, BRCA2, AR and IGF-I expression in prostate cancer: correlation between RT-qPCR and immunohistochemical detection.
Rabiau N; Déchelotte P; Adjakly M; Kemeny JL; Guy L; Boiteux JP; Kwiatkowski F; Bignon YJ; Bernard-Gallon D
Oncol Rep; 2011 Sep; 26(3):695-702. PubMed ID: 21667031
[TBL] [Abstract][Full Text] [Related]
46. Microvessel density as a molecular marker for identifying high-grade prostatic intraepithelial neoplasia precursors to prostate cancer.
Sinha AA; Quast BJ; Reddy PK; Lall V; Wilson MJ; Qian J; Bostwick DG
Exp Mol Pathol; 2004 Oct; 77(2):153-9. PubMed ID: 15351240
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides.
Eder IE; Culig Z; Ramoner R; Thurnher M; Putz T; Nessler-Menardi C; Tiefenthaler M; Bartsch G; Klocker H
Cancer Gene Ther; 2000 Jul; 7(7):997-1007. PubMed ID: 10917202
[TBL] [Abstract][Full Text] [Related]
48. Androgen receptor versus erbB-1 and erbB-2 expression in human prostate neoplasms.
Brys M; Stawinska M; Foksinski M; Barecki A; Zydek C; Miekos E; Krajewska WM
Oncol Rep; 2004 Jan; 11(1):219-24. PubMed ID: 14654929
[TBL] [Abstract][Full Text] [Related]
49. Expression profile of prostate-specific antigen messenger RNA assessed by in situ hybridization is a novel prognostic marker for patients with untreated prostate cancer.
Tsurusaki T; Koji T; Sakai H; Kanetake H; Saito Y
Clin Cancer Res; 1998 Sep; 4(9):2187-94. PubMed ID: 9748138
[TBL] [Abstract][Full Text] [Related]
50. Dysregulation of annexin I protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer.
Kang JS; Calvo BF; Maygarden SJ; Caskey LS; Mohler JL; Ornstein DK
Clin Cancer Res; 2002 Jan; 8(1):117-23. PubMed ID: 11801547
[TBL] [Abstract][Full Text] [Related]
51. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer.
Agoulnik IU; Vaid A; Nakka M; Alvarado M; Bingman WE; Erdem H; Frolov A; Smith CL; Ayala GE; Ittmann MM; Weigel NL
Cancer Res; 2006 Nov; 66(21):10594-602. PubMed ID: 17079484
[TBL] [Abstract][Full Text] [Related]
52. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer.
Zhigang Z; Wenlv S
World J Surg Oncol; 2004 May; 2():13. PubMed ID: 15132743
[TBL] [Abstract][Full Text] [Related]
53. Androgen receptor expression in clinically localized prostate cancer: immunohistochemistry study and literature review.
Qiu YQ; Leuschner I; Braun PM
Asian J Androl; 2008 Nov; 10(6):855-63. PubMed ID: 18958349
[TBL] [Abstract][Full Text] [Related]
54. Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.
Jackson KM; Frazier MC; Harris WB
Anticancer Res; 2007; 27(3B):1483-8. PubMed ID: 17595765
[TBL] [Abstract][Full Text] [Related]
55. Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status.
Wetherill YB; Fisher NL; Staubach A; Danielsen M; de Vere White RW; Knudsen KE
Cancer Res; 2005 Jan; 65(1):54-65. PubMed ID: 15665279
[TBL] [Abstract][Full Text] [Related]
56. Differential expression of MSX2 in nodular hyperplasia, high-grade prostatic intraepithelial neoplasia and prostate adenocarcinoma.
Chua CW; Chiu YT; Yuen HF; Chan KW; Wang X; Ling MT; Wong YC
APMIS; 2010 Dec; 118(12):918-26. PubMed ID: 21091772
[TBL] [Abstract][Full Text] [Related]
57. Distant metastases from prostatic carcinoma express androgen receptor protein.
Hobisch A; Culig Z; Radmayr C; Bartsch G; Klocker H; Hittmair A
Cancer Res; 1995 Jul; 55(14):3068-72. PubMed ID: 7541709
[TBL] [Abstract][Full Text] [Related]
58. The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue.
Nakada SY; di Sant'Agnese PA; Moynes RA; Hiipakka RA; Liao S; Cockett AT; Abrahamsson PA
Cancer Res; 1993 May; 53(9):1967-70. PubMed ID: 8481896
[TBL] [Abstract][Full Text] [Related]
59. Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer.
Li P; Yu X; Ge K; Melamed J; Roeder RG; Wang Z
Am J Pathol; 2002 Oct; 161(4):1467-74. PubMed ID: 12368219
[TBL] [Abstract][Full Text] [Related]
60. Androgen receptor immunohistochemistry on paraffin-embedded tissue.
Loda M; Fogt F; French FS; Posner M; Cukor B; Aretz HT; Alsaigh N
Mod Pathol; 1994 Apr; 7(3):388-91. PubMed ID: 8058713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
